Literature DB >> 1643428

Malignant melanoma of the nasal cavity and nasopharynx treated with cisplatin and accelerated hyperfractionated radiation.

M Albertsson1, J Tennvall, T Andersson, A Biörklund, A Elner, L Johansson.   

Abstract

Primary malignant melanoma of the nasal cavity and paranasal sinuses is an uncommon disease, accounting for only 0.5-2% of all malignant melanomas. The primary treatment has been surgery. The frequency of local recurrence is high and recurrence is also the major determinant of treatment failure. Here we report on six patients with locally advanced disease, four of whom were too advanced for surgery, who were treated with accelerated hyperfractionated radiation in combination with cis-platinum. Three of four patients treated for local recurrent disease achieved a local cure and died of disseminated disease after 9-21 months. One patient given preoperative cisplatin and radiation is still alive with no evidence of disease 34 months after the completion of treatment. The present protocol may be a useful approach to obtain local control with the possibility of long-term cure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1643428     DOI: 10.1097/00008390-199207000-00004

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  2 in total

1.  Unknown primary nasopharyngeal melanoma presenting as severe recurrent epistaxis and hearing loss following treatment and remission of metastatic disease: A case report and literature review.

Authors:  Saïd C Azoury; Joseph G Crompton; David M Straughan; Nicholas D Klemen; Emily S Reardon; Tatiana H Beresnev; Marybeth S Hughes
Journal:  Int J Surg Case Rep       Date:  2015-04-01

2.  Survival benefits from concomitant chemoradiotherapy before radical surgery in stage IVA sinonasal mucosal melanoma?

Authors:  Anna Hafström; Eva Brun; Simon Persson; Johanna Sjövall; Peter Wahlberg; Lennart Greiff
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-11-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.